IPPON

Ippon-Bio is a biopharmaceutical company specializing in the discovery and development of selective modulators of Protein Phosphatase 1 (PP1) to treat neurodegenerative disorders. By utilizing a fragment-based drug discovery approach, the company targets specific PP1 regulatory subunits to achieve high selectivity and minimize off-target effects. Their primary therapeutic focus includes Alzheimer's and Parkinson's diseases, where they aim to restore synaptic plasticity and proteostasis. Founded as a spin-off from the University of Lille and CNRS, Ippon-Bio is advancing a pipeline of small molecule candidates through pre-clinical development. The company's innovative strategy addresses the historical difficulty of targeting phosphatases, potentially opening new avenues for treating protein misfolding diseases.